Cardiovascular Biomarkers and Calculated Cardiovascular Risk in
                    Orally Treated Type 2 Diabetes Patients: Is There a Link?

Aleksandra Markova; Mihail Boyanov; Deniz Bakalov; Atanas Kundurdjiev; Adelina Tsakova

doi:10.1055/a-1199-2378

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2021; 53(01): 41-48
DOI: 10.1055/a-1199-2378

Endocrine Care

Cardiovascular Biomarkers and Calculated Cardiovascular Risk in Orally Treated Type 2 Diabetes Patients: Is There a Link?

Aleksandra Markova

¹Department of Internal Medicine, Clinic of Endocrinology and Metabolism, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Mihail Boyanov

¹Department of Internal Medicine, Clinic of Endocrinology and Metabolism, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Deniz Bakalov

¹Department of Internal Medicine, Clinic of Endocrinology and Metabolism, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Atanas Kundurdjiev

²Department of Internal Medicine, Clinic of Nephrology, University Hospital “St. Ivan Rilski”, Medical University Sofia, Sofia, Bulgaria

,

Adelina Tsakova

³Department of Clinical Laboratory and Clinical Immunology, Central Clinical Laboratory, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

› Author Affiliations

Abstract

The aim of the study was to test the correlation of serum levels of asymmetric dimethylarginine (ADMA), endothelin 1 (ET-1), N-terminal brain natriuretic pro-peptide (NT-proBNP), and placental growth factor (PIGF-1) with estimated cardiovascular (CV) risk. The study group was composed of 102 women and 67 men with type 2 diabetes, having their glycemic and metabolic parameters assessed. All were on oral antidiabetic drugs. Serum levels of NT-proBNP and PIGF-1 were measured by electro-hemi-luminescence on an Elecsys 2010 analyzer. Enzymatic immunoassays were used for ADMA and ET-1. The Framingham Risk Score (FRS), the UKPDS 2.0 and the ADVANCE risk engines were used to calculate cardiovascular risks while statistical analysis was performed on SPSS. Levels of PIGF-1 showed no correlation with the calculated CV risks. The same was true for ADMA, except for a weak correlation with the UKPDS-based 10-year risk for stroke (Pearsons’s R=0.167, p=0.039). Plasma levels of ET-1 were correlated with the UKPDS-based 10-year risk for stroke (R=0.184, p=0.032) and fatal stroke (R=0.215, p=0.012) only. NT-proBNP was significantly correlated with all CV risk calculations: ADVANCE-based 4-yr risk (Spearman’s Rho=0.521, p<0.001); UKPDS-based 10-year risk for: CHD (Rho=0.209, p=0.01), fatal CHD (Rho=0.282, p<0.001), stroke (Rho=0.482, p<0.001), fatal stroke (Rho=0.505, p<0.001); and 10-year FRS risk (Rho=0.246, p=0.002). In conclusion, ADMA and PIGF-1 did not seem useful in stratifying CV risk while ET-1 is linked to the risk of stroke, and NT-proBNP to all CV risk estimations.

Key words:

NT-proBNP - ADMA - endothelin-1 - risk calculators - correlations - PIGF-1

Full Text

References

References
1 Einarson TR, Acs A, Ludwig C. et al. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018; 17: 83
2 Fox CS, Golden SH, Anderson C. et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38: 1777-1803
3 Rydén L, Grant PJ, Anker SD. et al. Diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J 2013; 34: 3035-3087
4 Wells BJ, Roth R, Nowacki AS. et al. Prediction of morbidity and mortality in patients with type 2 diabetes. Peer J 2013; 1: e87
5 Jellinger PS, Handelsman Y, Rosenblit PD. et al. The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE). Endocr Pract 2017; 23: 1-87
6 National Institute for Health Care and Excellence (NICE). Cardiovascular disease: Risk assessment and reduction, including lipid modification. Clinical Guideline NICE CG181, July 2014, Last updated: Sep 2016; https://www.nice.org.uk/guidance/cg181
7 Allan GM, Nouri F, Korownyk C. et al. Agreement among cardiovascular disease risk calculators. Circulation. 2013; 127: 1948-1956
8 Kengne AP. The ADVANCE cardiovascular risk model and current strategies for cardiovascular disease risk evaluation in people with diabetes. Cardiovasc J Afr 2013; 24: 376-381
9 Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: Comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 2004; 21: 238-245
10 Fujihara K, Suzuki H, Sato A. et al. Comparison of the Framingham risk score, UK prospective diabetes Study (UKPDS) risk engine, Japanese atherosclerosis longitudinal study-Existing cohorts combine (JALS-ECC) and maximum carotid intima-media thickness for predicting coronary artery stenosis in patients with asymptomatic type 2 diabetes. J Atheroscler Thromb 2014; 21: 799-815
11 Pokharel DR, Khadka D, Sigdel M. et al. Estimation of 10-year risk of coronary heart disease in Nepalese patients with type 2 diabetes: Framingham versus United Kingdom prospective diabetes study. N Am J Med Sci 2015; 7: 347-355
12 Echouffo-Tcheugui JB, Kengne AP. Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes Metab 2013; 39: 389-396
13 Bansal D, Nayakallu RSR, Gudala K. et al. Agreement between framingham risk score and united kingdom prospective diabetes study risk engine in identifying high coronary heart disease risk in North Indian population. Diabetes Metab J 2015; 39: 321-327
14 Simmons RK, Coleman RL, Price HC. et al. Performance of the UK prospective diabetes study risk engine and the framingham risk equations in estimating cardiovascular disease in the EPIC- norfolk cohort. Diabetes Care 2009; 32: 708-713
15 van der Leeuw J, Beulens JWJ, van Dieren S. et al. Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc 2016; 5
16 Sciacqua A, Grillo N, Quero M. et al. Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients. Int J Mol Sci 2012; 13: 13804-13815
17 Anderssohn M, Schwedhelm E, Lüneburg N. et al. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010; 7: 105-118
18 Ganz T, Wainstein J, Gilad S. et al. Serum asymmetric dimethylarginine and arginine levels predict microvascular and macrovascular complications in type 2 diabetes mellitus. Diabetes Metab Res Rev 2017;
19 Hsu CP, Hsu PF, Chung MY. et al. Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: Relation with the glycemic control. Cardiovasc Diabetol 2014; 13: 156
20 Jawalekar SL, Karnik A, Bhutey A. Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. Bioch Res Int 2013; 189430
21 Chen S, Li N, Deb-Chatterji M, Dong Q. et al. Asymmetric Dimethyarginine as marker and mediator in Ischemic stroke. Int J Mol Sci 2012; 13: 15983-16004
22 Kalogeropoulou K, Mortzos G, Migdalis I. et al. Carotid atherosclerosis in type 2 diabetes mellitus: Potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology 2002; 53: 279-285
23 Zhang C-L, Xie S, Qiao X. et al. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: A PRISMA-compliant meta-analysis. Medicine 2017; 96: e9342
24 El-Mesallamy H, Suwailem S, Hamdy N. Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm 2007; 73635
25 Ju C, Ye M, Li F. Plasma brain natriuretic peptide, endothelin-1, and matrix metalloproteinase 9 expression and significance in type 2 diabetes mellitus patients with ischemic heart disease. Med Sci Monit 2015; 21: 2094-2099
26 Kartamihardja AS. Correlation between transient ischemic dilation index and endothelin-1 level in patients with Type 2 diabetes mellitus. World J Nucl Med 2016; 15: 109
27 Sayama H, Nakamura Y, Saito etal. Does the plasma endothelin-1 concentration reflect atherosclerosis in the elderly?. Gerontology 1999; 45: 312-316
28 Li W, Kelly-Cobbs AI, Mezzetti EM. et al. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. Can J Physiol Pharmacol 2010; 88: 788-795
29 James-Todd T, Cohen A, Wenger J. et al. Time-specific placental growth factor (PlGF) across pregnancy and infant birth weight in women with preexisting diabetes. Hypertens Pregnancy 2016; 35: 436-446
30 Mishra RK, Beatty AL, Jaganath R. et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. J Am Heart Assoc 2014; 3: e000907
31 Wolsk E, Claggett B, Pfeffer MA. et al. Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. J Am Heart Assoc 2017; 6: e004743.
32 Resl M, Clodi M, Vila G. et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart 2016; 102: 1963-1968
33 Kavaric N, Klisic A, Ninic A. Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes. Open Med 2018; 13: 610-617
34 Vassalle C, Sabatino L, Cecco Pdi. et al. Relationship between bone health biomarkers and cardiovascular risk in a general adult population. Diseases 2017; 5: 24
35 Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia RepoRt of a WHO/IDf ConsultatIon. 2006; https://apps.who.int/iris/handle/10665/43588
36 WHO. Obesity: Preventing and managing the global epidemic. World Health Organization: Technical Report Series. WHO Technical Report Series, no. 894. 2000; /www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/
37 Davies MJ, D’Alessio DA, Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701
38 Catapanoc AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058
39 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
40 Triches CB, Mayer S, Quinto BMR. et al. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension. J Clin Hypertens 2018; 20: 935-941
41 Borgeraas H, Hertel JK, Svingen GFT. et al. Association between body mass index, asymmetric dimethylarginine and risk of cardiovascular events and mortality in norwegian patients with suspected stable angina pectoris. PLoS One 2016; 11: e0152029
42 Seligman BGS, Biolo A, Polanczyk CA. et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2000; 23: 1395-1400
43 Kostov K, Blazhev A, Atanasova M. et al. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in pre-hypertensive and hypertensive patients with type 2 diabetes. Int J Mol Sci 2016; 17: 1182
44 Kuo YR, Chien CM, Kuo MJ. et al. Endothelin-1 expression associated with lipid peroxidation and nuclear factor-KB activation in type 2 diabetes mellitus patients with angiopathy and limb amputation. Plast Reconstr Surg 2016; 137: 187e-195e
45 Harris AK, Hutchinson JR, Sachidanandam K. et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: Role of endothelin-1. Diabetes 2005; 54: 2638-2644
46 Miyauchi T, Sakai S. Endothelin and the heart in health and diseases. Peptides 2019; 111: 77-88
47 Sachidanandam K, Hutchinson JR, Elgebaly MM. et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: Link to endothelin-1. Am J Physiol Regul Integr Comp Physiol 2009; 296: R952-R959
48 Sánchez SS, Aybar MJ, Velarde MS. et al. Relationship between plasma Endothelin-1 and glycemic control in type 2 diabetes mellitus. Horm Metab Res 2001; 33: 748-751
49 Gao R, Wang J, Zhang S. et al. The value of combining plasma d-dimer and endothelin-1 levels to predict no-reflow after percutaneous coronary intervention of st-segment elevation in acute myocardial infarction patients with a type 2 diabetes mellitus history. Med Sci Monit 2018; 24: 3549-3556
50 Pernow J, Shemyakin A, Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. In: Life Sci 2012; 91: 507-516
51 Harris AK, Elgebaly MM, Li W. et al. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1213-R1219
52 Ahn HR, Shin MH, Yun WJ. et al. Comparison of the framingham risk score, UKPDS risk engine, and SCORE for predicting carotid atherosclerosis and peripheral arterial disease in Korean type 2 diabetic patients. Korean J Fam Med 2011; 32: 189-196
53 Jiao FF, Lam CLK, Fung C. et al. Comparison of four cardiovascular risk prediction functions among Chinese patients with diabetes mellitus in the primary care setting. J Diabetes Investig 2014; 5: 606-614
54 Goliasch G, Silbernagel G, Kleber ME. et al. Refining Long-Term Prediction of Cardiovascular Risk in Diabetes-The VILDIA Score. Sci Rep 2017; 7: 4700
55 Wind AE, Gorter KJ, van den Donk M. et al. Impact of UKPDS risk estimation added to a first subjective risk estimation on management of coronary disease risk in type 2 diabetes - An observational study. Prim Care Diabetes 2016; 10: 27-35